Medicare AdvantageCoverageMedium impact
MA08.124e, Cemiplimab-rwlc (Libtayo®)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross Medicare Advantage expanded coverage for Cemiplimab-rwlc (Libtayo) effective 12/29/2025 to include four new cancer indications: Anal Carcinoma, Small Bowel Adenocarcinoma, Rectal Cancer, and Colon Cancer. The policy also revised squamous cell skin cancer adjuvant treatment criteria and removed ICD-10 CM codes from the policy document, requiring providers to report the most appropriate diagnosis codes manually.
Action Required
By December 29, 2025: Billing team must update billing system and clinical decision support to recognize Cemiplimab-rwlc (Libtayo) as covered for the four newly added cancer indications (Anal Carcinoma, Small Bowel Adenocarcinoma, Rectal Cancer, Colon Cancer) in addition to existing BCC and CSCC indications. Providers must be notified that ICD-10 codes are no longer listed in the policy—they must manually select and report the most appropriate diagnosis code supporting medical necessity criteria documented in the policy. Update prior authorization workflows and claim validation rules to accept HCPCS code J9119 with the expanded diagnoses. Ensure billing software validates that claims include proper diagnosis coding that aligns with the coverage criteria (e.g., for Colon Cancer: dMMR/MSI-H status, POLE/POLD1 mutations, or TMB >50 mut/Mb, plus appropriate clinical scenario). Claims submitted without compliant diagnosis coding or for non-covered scenarios will be denied.